Education
About Us
Working with TipRanks
Follow Us
Candel Therapeutics (CADL)
NASDAQ:CADL
CADL Stock Chart & Stats
$5.45
$0.00(0.00%)
At close: 4:00 PM EST
$5.45
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$4.25 - $14.60
Previous CloseN/A
Volume524.53K
Average Volume (3M)704.57K
Market Cap
$292.61M
Enterprise Value$200.21M
Total Cash (Recent Filing)$86.96M
Total Debt (Recent Filing)$6.23M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Mar 26, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding54,898,304
10 Day Avg. Volume767,183
30 Day Avg. Volume704,566
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)4.15
Price to Sales (P/S)0.00
P/FCF Ratio-10.17
Enterprise Value/Market Cap0.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-215.97
Enterprise Value/Ebitda-9.65
Forecast
1Y Price Target
$18.33Price Target Upside236.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.45
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyRobust Phase 3 data demonstrates the safety and efficacy of CAN-2409 in intermediate-to-high risk prostate cancer as well as parallel positive Phase 2 survival data in NSCLC.
Market StrategyCandel plans to use a capital-efficient adaptive-commercialization strategy by partnering with external specialized networks for market access, pricing, and stakeholder engagement.
Regulatory ProgressCandel remains actively supported by the FDA, confirming that no additional clinical studies to bridge the clinical and commercial materials are required for the BLA.
Bears Say
Cardiovascular RiskThe use of Androgen Deprivation Therapy (ADT) is associated with an elevated risk of a major adverse cardiovascular event among prostate cancer patients.
Development PauseCandel has paused their development of CAN-2409 for borderline resectable pancreatic ductal adenocarcinoma, despite the encouraging 31.4mo mOS in the phase 2 study.
Financial ChallengesThe recent debt deal with Trinity Capital should help keep CAN-2409 in NSCLC in Candel’s hands though we expect additional financing may be needed in the next few years.
Candel Therapeutics News
CADL FAQ
What was Candel Therapeutics’s price range in the past 12 months?
Candel Therapeutics lowest stock price was $4.25 and its highest was $14.60 in the past 12 months.
What is Candel Therapeutics’s market cap?
Candel Therapeutics’s market cap is $292.61M.
When is Candel Therapeutics’s upcoming earnings report date?
Candel Therapeutics’s upcoming earnings report date is Mar 26, 2026 which is in 106 days.
How were Candel Therapeutics’s earnings last quarter?
Candel Therapeutics released its earnings results on Nov 13, 2025. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.185 by -$0.025.
Is Candel Therapeutics overvalued?
According to Wall Street analysts Candel Therapeutics’s price is currently Undervalued.
Does Candel Therapeutics pay dividends?
Candel Therapeutics does not currently pay dividends.
What is Candel Therapeutics’s EPS estimate?
Candel Therapeutics’s EPS estimate is -0.25.
How many shares outstanding does Candel Therapeutics have?
Candel Therapeutics has 54,898,304 shares outstanding.
What happened to Candel Therapeutics’s price movement after its last earnings report?
Candel Therapeutics reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.185. Following the earnings report the stock price went down -6.301%.
Which hedge fund is a major shareholder of Candel Therapeutics?
Currently, no hedge funds are holding shares in CADL
Candel Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.33 (236.33% Upside)
$18.33 (236.33% Upside)
Blogger Sentiment
Bullish
CADL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 353.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.2%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.77%
12-Months-Change
Fundamentals
Return on Equity
-70.17%
Trailing 12-Months
Asset Growth
335.00%
Trailing 12-Months
Company Description
Candel Therapeutics
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
CADL Stock 12 Month Forecast
Average Price Target
$18.33
▲(236.33% Upside)
Technical Analysis
Tonix Pharma
―
Quantum-Si
―
Humacyte
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
19.77% Insiders
17.93% Mutual Funds
5.60% Other Institutional Investors
50.52% Public Companies and
Individual Investors